Kalydeco Tablet, Film Coated
NDC Package 51167-200-01
Package Information
Kalydeco (ivacaftor) tablets is a medication used to treat cystic fibrosis in certain people (those with an abnormal "CFTR" gene). This formulation utilizes a tablet, film coated delivery system. Marketed by Vertex Pharmaceuticals Incorporated, this product is identified by NDC 51167-200 and is authorized under FDA application NDA203188.
Identification & Billing
- RxCUI: 1243046 - ivacaftor 150 MG Oral Tablet
- RxCUI: 1243052 - kalydeco 150 MG Oral Tablet
- RxCUI: 1243052 - ivacaftor 150 MG Oral Tablet [Kalydeco]
- RxCUI: 1243052 - Kalydeco 150 MG Oral Tablet
- RxCUI: 1606862 - ivacaftor 50 MG Oral Granules
Clinical Specifications
- Chloride Channel Activation Potentiators - [MoA] (Mechanism of Action)
- Cystic Fibrosis Transmembrane Conductance Regulator Potentiator - [EPC] (Established Pharmacologic Class)
- Cytochrome P450 2C9 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A Inhibitors - [MoA] (Mechanism of Action)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 51167 - Vertex Pharmaceuticals Incorporated
- 51167-200 - Kalydeco
- 51167-200-01 - 4 BLISTER PACK in 1 CARTON / 14 TABLET, FILM COATED in 1 BLISTER PACK
- 51167-200 - Kalydeco
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (51167-200). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51167-200-01 identifies a specific commercial package of 4 blister pack in 1 carton / 14 tablet, film coated in 1 blister pack of Kalydeco, a human prescription drug labeled by Vertex Pharmaceuticals Incorporated. This product is billed for "EA" each discreet unit and contains an estimated amount of 4 billable units per package. This tablet, film coated is formulated for oral use and contains ivacaftor as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Vertex Pharmaceuticals Incorporated on January 31, 2012. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat cystic fibrosis in certain people (those with an abnormal "CFTR" gene). It may help to improve breathing, reduce the risk of lung infections, and improve weight gain.
How is this Vertex Pharmaceuticals Incorporated product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51167020001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 4 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.